Latest collaboration video

Watch the video on our entrepreneurial collaboration with Cambridge Judge Business School. The ‘Accelerate Cambridge’ Life Sciences programme aims to identify, train and mentor early-stage life science ventures in Cambridge.

Read more about this collaboration

 


LabTalk is AstraZeneca’s science-focused blog where you can hear from scientists, researchers and academics discussing novel ideas, research and innovation.

Risk_and_reoccurrence_THM 31 August 2015

Early intervention: aiming to avert the consequences of minor stroke and transient ischaemic attacks

CRISPR Conference

We are pleased to announce the inaugural Sanger Institute-AstraZeneca conference centred on the application of CRISPR technology to the understanding and treatment of human disease. Read More

CRISPR Conference


Latest press releases

Positive Phase III results demonstrate efficacy of antibiotic medicine CAZ-AVI in complicated Urinary Tract Infections
2 September 2015
AstraZeneca enters license agreement with Daiichi Sankyo for development and commercialisation of FluMist in Japan
2 September 2015
AstraZeneca and Valeant Pharmaceuticals to partner on brodalumab
1 September 2015
PEGASUS-TIMI 54 sub-analysis shows importance of continuing treatment with BRILINTA beyond one year following a heart attack
31 August 2015
AstraZeneca to present further research into long-term prevention of cardiovascular events for patients with a history of heart attack at ESC Congress 2015
29 August 2015
AstraZeneca appoints Dr Sean Bohen as Executive Vice President of Global Medicines Development and Chief Medical Officer
24 August 2015
AstraZeneca and Peregrine Pharmaceuticals to collaborate on immuno-oncology combination clinical trial
24 August 2015
Medimmune enters into strategic cancer vaccine collaboration and license agreement with Inovio Pharmaceuticals
10 August 2015
AstraZeneca and Heptares Therapeutics enter agreement to develop novel immuno-oncology treatments
6 August 2015
MedImmune and Mirati Therapeutics partner on immuno-oncology combination in lung cancer
5 August 2015
AstraZeneca and Isis Pharmaceuticals to discover and develop antisense drugs for cardiovascular, metabolic and renal diseases
3 August 2015
AstraZeneca PLC H1 2015 results
30 July 2015